Your Notifications
All done, no notifications

What is Chronic Lymphocytic Leukemia (CLL)?

Chronic lymphocytic leukaemia (CLL) is a blood cancer in which abnormal lymphocytes, most commonly B lymphocytes, accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL usually develops slowly and may not cause symptoms early on.

The disease can disrupt normal blood cell production and function, potentially leading to anaemia, increased susceptibility to infections, or low platelet counts. CLL is closely related to small lymphocytic lymphoma (SLL), with the distinction primarily based on where the abnormal lymphocytes are found.

What is the Importance of Timely Treatment?

A timely diagnosis helps determine the extent and biological characteristics of CLL and whether treatment is needed. Not every person diagnosed with CLL needs immediate treatment. Patients without symptoms or with stable disease may be managed with active surveillance, including regular blood tests and clinical assessments.

What are the Common Symptoms of Chronic Lymphocytic Leukemia (CLL)?

  • Persistent fatigue or weakness
  • Painless swelling of lymph nodes in the neck, armpits, or groin
  • Frequent or recurrent infections
  • Unexplained weight loss
  • Fever without an obvious infection
  • Drenching night sweats
  • Easy bruising or bleeding
  • Shortness of breath related to anemia
  • Abdominal fullness or discomfort due to an enlarged spleen

Causes and Risk Factors of Chronic Lymphocytic Leukemia (CLL)

Causes

  • The exact cause of CLL is not known. The disease develops when genetic and molecular changes cause abnormal B lymphocytes to survive and accumulate. These abnormal cells can gradually build up in the blood, bone marrow, lymph nodes, and spleen.

Risk Factors

  • Increasing age
  • Male sex
  • Having a first-degree relative with CLL or another related lymphoid cancer
  • Certain inherited genetic susceptibility factors

Latest Research and Technologies in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Turkey

  • CLL treatment has advanced with targeted therapies and molecular risk assessment, including BTK inhibitors and BCL2 inhibitors, which may be combined with anti-CD20 antibodies. Genetic and molecular testing, including TP53 abnormalities and IGHV mutation status, helps guide treatment selection, while newer options such as the non-covalent BTK inhibitor pirtobrutinib and cellular therapies expand treatment options for selected patients with relapsed or refractory CLL.

Treatment options for Chronic Lymphocytic Leukemia (CLL)

Active surveillance: Patients with early or asymptomatic CLL may be monitored regularly without immediate treatment.

Combination therapy: Targeted medicines may be combined with antibodies or other agents depending on the patient's disease characteristics.

Chemotherapy : Traditional chemotherapy has a more limited role than in the past but may still be considered in specific circumstances.

CAR-T Cell Therapy : It is specifically approved as a highly effective option for adults with relapsed or refractory CLL who have already exhausted standard BTK and BCL-2 inhibitor treatments.

Cost Start From 80000Explore Options

Stem cell transplantation : Allogeneic stem cell transplantation may be considered for a small number of carefully selected patients with high-risk, treatment-resistant disease.

Cost Start From 20000Explore Options

MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Chronic Lymphocytic Leukemia (CLL) patients in Turkey. These services include:

  • Physical activity: Appropriate activity can help maintain muscle strength, mobility, and endurance.
  • Physiotherapy: May help with weakness, reduced mobility, or treatment-related physical limitations.
  • Nutritional support: Helps maintain adequate nutrition during treatment and recovery.
  • Fatigue management: Energy conservation, sleep support, gradual activity, and appropriate rest may help manage cancer-related fatigue.
  • Psychological support: Counselling and supportive-care services can help patients cope with the emotional and social effects of living with CLL.
  • CLL medicines primarily target abnormal lymphocytes and the pathways that allow them to survive. Commonly used treatments include BTK inhibitors. Anti-CD20 monoclonal antibodies. Newer medicines, including non-covalent BTK inhibitors, may be considered in certain relapsed or treatment-resistant cases. Supportive medicines may also be used to manage infections, anemia, treatment-related side effects, or other complications.

Instantly Connect with our Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8

Hospitals for Chronic Lymphocytic Leukemia (CLL) in Turkey

Medipol Bahçelievler Hospital: Top Doctors, and Reviews
Medipol Bahçelievler Hospital

Istanbul, Turkey

Medipol Bahcelievler Hospital is a medical institution providing a full range of medical and individualized approaches to its patients. Medipol has the ambition to bring high quality and maximum security to people in need by employing state-of-the-art technologies in medicine. They ensure that the health of the patients is improved by fashioning unique physician specialty treatment programs.

Medipol Bahcelievler Hospital provides an exceptional position in the healthcare industry with a policy of clear communication, professionalism, and reliability to patient expectations. Medipol Bahçelievler Hospital is situated in the European Side of Istanbul, dedicated to 24-hour health care for you and your loved ones, equipped with a fully functional operation theatre and ICUs with state-of-the-art equipment, laboratory, emergency, and advanced treatment rooms

Message Us

296

PROCEDURE

19

DOCTORS IN 16 SPECIALITIES

19+

FACILITIES & AMENITIES

Baskent University Istanbul Hospital: Top Doctors, and Reviews
Baskent University Istanbul Hospital

Istanbul, Turkey

Baskent University Istanbul Hospital located in Istanbul, Turkey is accredited by ISO. Also listed below are some of the most prominent infrastructural details:

  • 13.000 square meters indoor area
  • Aesthetically designed Inpatient rooms
  • Latest healthcare equipments
  • 105 bed capacity
  • 5 operating rooms
  • 38 bed capacity in the Intensive Care Unit
  • 609 healthcare personnel and healthcare professors
  • Translation services for International patients
Message Us

283

PROCEDURE

22

DOCTORS IN 14 SPECIALITIES

17+

FACILITIES & AMENITIES

Istanbul Oncology Hospital: Top Doctors, and Reviews
Istanbul Oncology Hospital

Istanbul, Turkey

Istanbul Oncology Hospital has a new hospital building with the latest technology devices in the healthcare industry and was designed keeping in mind all the possible needs of the patients.

Message Us

187

PROCEDURE

11

SPECIALITIES

8+

FACILITIES & AMENITIES

Our Services to better your experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Why Choose Turkey for Chronic Lymphocytic Leukemia (CLL) Treatment?

  • Experienced hematologists: Specialists with expertise in leukemia diagnosis, risk assessment, targeted therapy, and long-term disease management.
  • Advanced diagnostic facilities: Flow cytometry, cytogenetic testing, FISH, molecular testing, and advanced imaging can support diagnosis and treatment planning.
  • Modern targeted therapies: Eligible patients may have access to BTK inhibitors, BCL2 inhibitors, monoclonal antibodies, and newer treatment approaches.
  • Multidisciplinary care: Hematologists, oncologists, pathologists, radiologists, transplant specialists, and supportive-care teams can collaborate on complex cases.
  • International patient support: Many major hospitals provide dedicated services for international patients, including treatment coordination, documentation, accommodation, travel assistance, and follow-up planning.

Frequently Asked Questions

There is no fixed recovery period for CLL because it is often a long-term condition that may be monitored or treated over different periods. Recovery from active treatment depends on the therapy used, disease response, side effects, and the patient's overall health.

Yes. Most people with CLL can walk and remain physically active if their health permits. Activity may need to be adjusted during periods of significant fatigue, anemia, infection, low blood counts, or treatment-related side effects.

Many specialised cancer centres in Turkey offer advanced diagnostic facilities such as flow cytometry, FISH, and molecular testing, along with modern targeted therapies for eligible CLL patients. Availability varies by hospital and individual clinical circumstances.

Many major Turkish hospitals have international patient departments that assist with medical appointments, treatment coordination, travel documentation, accommodation, interpretation, and follow-up arrangements.

Look for a centre with experienced hematologists, specialised leukemia services, advanced flow cytometry and molecular diagnostics, access to targeted therapies, and multidisciplinary care. For complex or relapsed CLL, consider whether the centre offers advanced treatment options and, when clinically appropriate, transplant or cellular-therapy services.

CLL outcomes vary by age, disease stage, genetic and molecular characteristics, overall health, prior treatments, and response to therapy. Many patients can achieve prolonged disease control with modern treatment, but CLL may require long-term monitoring.

Turkey has specialised haematology and oncology centres with experience in diagnosing and treating leukemia, including CLL. Patients should consider the specialist's experience with CLL and the hospital's available diagnostic, treatment, transplant, and supportive-care facilities.

Risks vary by treatment. Targeted medicines can cause treatment-specific effects such as infections, bleeding, heart-rhythm problems, high blood pressure, or tumour lysis syndrome. Immunotherapy can cause infusion or immune-related reactions, while chemotherapy can cause low blood counts, infections, nausea, and fatigue. Your doctor will assess individual risks before treatment.

After diagnosis, consult a haematologist to confirm it and assess the disease stage and biological characteristics. Ask about blood test results, genetic and molecular findings, whether treatment is required immediately, available treatment options, and the recommended monitoring schedule.

CLL does not typically cause permanent physical deformities. However, advanced disease or treatment-related complications can sometimes affect physical function or general health.

Yes. Fatigue, recurrent infections, enlarged lymph nodes, treatment side effects, emotional stress, and concerns about long-term disease management can affect quality of life. Physical activity, nutritional care, symptom management, and psychological support can help address these challenges.

Some people with early or asymptomatic CLL can remain stable for years without treatment and may be safely monitored through active surveillance. However, progressive CLL can cause worsening blood counts, enlarged lymph nodes or spleen, recurrent infections, and other complications. In some patients, CLL can transform into a more aggressive lymphoma.

There is no established way to completely prevent CLL because its exact cause is not known. Some risk factors, such as age and inherited susceptibility, cannot be changed. Maintaining overall health and discussing persistent or unexplained symptoms with a healthcare professional can support general well-being but cannot guarantee prevention.

Yes. CLL is more common in older adults and occurs more frequently in men than women. It is also more common among people of European ancestry than in some other populations. Having a close relative with CLL or a related lymphoid cancer can also increase risk.

Author

Dr. Vijita Jayan
Dr. Vijita Jayan

BPT, MPT (Neuro)

18 Years of Experience

With over 18 years of distinguished clinical experience, Dr. Vijita Jayan is a highly accomplished Clinical Director and Rehabilitation Specialist, renowned for her expertise in neuro-rehabilitation, functional recovery, and mobility-dependent case management. Her extensive practical knowledge enables her to design and implement individualized, evidence-based rehabilitation protocols that consistently yield measurable patient outcomes. A prolific researcher and academic writer, she has authored numerous peer-reviewed articles and research papers, significantly advancing the field of rehabilitative medicine. The recipient of multiple prestigious accolades, Dr. Jayan is widely regarded as one of the foremost authorities in Physical Medicine and Rehabilitation, continually shaping neuro-rehabilitative care through research, innovation, and clinical excellence. View More

Reviewer

Dr. Mohit Agarwal
Dr. Mohit Agarwal

Medical Oncologist

14 Years of Experience

One of the finest Oncologist in New Delhi, India, Dr. Mohit Agarwal has worked with several world class multidisciplinary hospitals over the years. Dr. Mohit Agarwal has over 14+ years of experience in his field. The doctor treats and manages a wide range of conditions such as Stomach Cancer, Rectal Cancer, Breast Cancer, Brain Cancer View More

Last Reviewed - January 2026